277 related articles for article (PubMed ID: 24488619)
1. The role of Wnt signaling and sclerostin in the pathogenesis of glucocorticoid-induced osteoporosis.
Guañabens N; Gifre L; Peris P
Curr Osteoporos Rep; 2014 Mar; 12(1):90-7. PubMed ID: 24488619
[TBL] [Abstract][Full Text] [Related]
2. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
[TBL] [Abstract][Full Text] [Related]
4. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
[TBL] [Abstract][Full Text] [Related]
5. Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.
Sato AY; Cregor M; Delgado-Calle J; Condon KW; Allen MR; Peacock M; Plotkin LI; Bellido T
J Bone Miner Res; 2016 Oct; 31(10):1791-1802. PubMed ID: 27163932
[TBL] [Abstract][Full Text] [Related]
6. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.
Ivanova MM; Dao J; Kasaci N; Friedman A; Noll L; Goker-Alpan O
Front Endocrinol (Lausanne); 2022; 13():1029130. PubMed ID: 36506070
[TBL] [Abstract][Full Text] [Related]
7. Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles?
Sapir-Koren R; Livshits G
Osteoporos Int; 2014 Dec; 25(12):2685-700. PubMed ID: 25030653
[TBL] [Abstract][Full Text] [Related]
8. Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions.
Weivoda MM; Oursler MJ
Curr Osteoporos Rep; 2014 Mar; 12(1):107-14. PubMed ID: 24477413
[TBL] [Abstract][Full Text] [Related]
9. [Wnt signaling and glucocorticoid-induced osteoporosis].
Ohnaka K
Clin Calcium; 2006 Nov; 16(11):1812-6. PubMed ID: 17079847
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin and Bone Aging: A Mini-Review.
Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
[TBL] [Abstract][Full Text] [Related]
11. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin and Dickkopf-1 in renal osteodystrophy.
Cejka D; Herberth J; Branscum AJ; Fardo DW; Monier-Faugere MC; Diarra D; Haas M; Malluche HH
Clin J Am Soc Nephrol; 2011 Apr; 6(4):877-82. PubMed ID: 21164019
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of Dickkopf-1 are indicative of Wnt/β-catenin downregulation and lower osteoblast signaling in children and adolescents with type 1 diabetes mellitus, contributing to lower bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Osteoporos Int; 2017 Mar; 28(3):945-953. PubMed ID: 27766367
[TBL] [Abstract][Full Text] [Related]
14. Role of Wnt-signaling inhibitors DKK-1 and sclerostin in bone fragility associated with Turner syndrome.
Chiarito M; Piacente L; Chaoul N; Pontrelli P; D'Amato G; Grandone A; Russo G; Street ME; Wasniewska MG; Brunetti G; Faienza MF
J Endocrinol Invest; 2022 Jun; 45(6):1255-1263. PubMed ID: 35237949
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins.
Winkler DG; Sutherland MS; Ojala E; Turcott E; Geoghegan JC; Shpektor D; Skonier JE; Yu C; Latham JA
J Biol Chem; 2005 Jan; 280(4):2498-502. PubMed ID: 15545262
[TBL] [Abstract][Full Text] [Related]
16. Sclerostin and DKK-1: two important regulators of bone metabolism in HIV-infected youths.
Mora S; Puzzovio M; Giacomet V; Fabiano V; Maruca K; Capelli S; Nannini P; Lombardi G; Zuccotti GV
Endocrine; 2015 Aug; 49(3):783-90. PubMed ID: 25596857
[TBL] [Abstract][Full Text] [Related]
17. [Wnt pathway and sclerostin as new targets for assessment and treatment of osteoporosis].
Alonso G; García-Martín A; Muñoz-Torres M
Med Clin (Barc); 2012 Dec; 139(14):634-9. PubMed ID: 22613824
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin and Pref-1 have differential effects on bone mineral density and strength parameters in adolescent athletes compared with non-athletes.
Fazeli PK; Ackerman KE; Pierce L; Guereca G; Bouxsein M; Misra M
Osteoporos Int; 2013 Sep; 24(9):2433-40. PubMed ID: 23579340
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.
Ke HZ; Richards WG; Li X; Ominsky MS
Endocr Rev; 2012 Oct; 33(5):747-83. PubMed ID: 22723594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
